ENBREL® is registered for use across 7 indications, including paediatric indications.1
ENBREL is indicated for the treatment of:
An RA patient with an increased risk of serious infections
An elderly-onset RA patient
A young RA patient worried about treatments that lose effectiveness over time
Before prescribing, please review full Product Information (PI).
ENBREL is listed on the Pharmaceutical Benefits Scheme (PBS).
Download a copy of the ENBREL Consumer Medicine Information (CMI) for your patient.
Before prescribing, please review Product Information available here
PBS Information: Authority required for the treatment of adults with severe active rheumatoid arthritis, active ankylosing spondylitis, severe active psoriatic arthritis and severe chronic plaque psoriasis. Authority required for the treatment of patients under 18 years with severe chronic plaque psoriasis. Private and public hospital authority required for the treatment of severe active juvenile idiopathic arthritis. This product is not listed on the PBS for the treatment of non-radiographic axial spondyloarthritis. Refer to PBS Schedule for full information.
Enbrel is a ®Registered Trademark.